Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.6371 -0.0027 (-0.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 260,237
Open 0.6369
Bid (Size) 0.6311 (100)
Ask (Size) 0.6500 (1,000)
Prev. Close 0.6398
Today's Range 0.6194 - 0.6650
52wk Range 0.4300 - 5.140
Shares Outstanding 9,362,444
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
From Vistagen
Via Business Wire
News headline image
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Vistagen
Via Business Wire

Performance

YTD
-6.2%
-6.2%
1 Month
+4.7%
+4.7%
3 Month
+23.5%
+23.5%
6 Month
-85.8%
-85.8%
1 Year
-75.8%
-75.8%

More News

Read More
News headline image
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
From Vistagen
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
VTGN DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Vistagen to Participate in Upcoming Investor Conferences
From Vistagen
Via Business Wire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?
Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?
Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?
The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market
What is the current price of Vistagen Therapeutics, Inc. - Common Stock?
The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.6371
When was Vistagen Therapeutics, Inc. - Common Stock last traded?
The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 05/21/26 04:00 PM ET
What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?
The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 5.96M
How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?
Vistagen Therapeutics, Inc. - Common Stock has 6M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.